Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial

被引：0
作者：
Mateos, Antonio Vega [1 ]
Alfaro, Hector Alejandro Vaquera [1 ]
Vasquez, Ana Cristina Tejada [1 ]
Lopez-Garcia, Yadith Karina [1 ]
Garcia-Salas, Gerardo [1 ]
Cantu, Olga [1 ]
Gomez-De Leon, Andres [1 ]
Gomez-Almaguer, David [1 ]
Tarin-Arzaga, Luz [1 ]
Gutierrez-Aguirre, Cesar Homero [1 ]
Colunga-Pedraza, Perla R. [1 ]
机构：
[1] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Serv Hematol, Monterrey, Mexico
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [1] Lonah Trial: A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
    Korula, Anu
    Jain, Hasmukh
    Ganesan, Prasanth
    Kulkarni, Uday
    Samuel, Prasanna
    Sengar, Manju
    Mathews, Vikram
    BLOOD, 2024, 144 : 30551 - 30552
  • [2] Low-Dose Radiation Therapy with Nivolumab in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of the Phase II Radvax Trial
    LaRiviere, Michael J.
    Vaziri, Tina
    Farwell, Michael
    Maity, Amit
    Paydar, Ima
    Schuster, Stephen J.
    Nasta, Sunita Dwivedy
    Chong, Elise A.
    Landsburg, Daniel J.
    Plastaras, John P.
    Svoboda, Jakub
    BLOOD, 2022, 140 : 3726 - 3727
  • [3] Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma
    Hwang, Yu-Yan
    Khong, Pek-Lan
    Kwong, Yok-Lam
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1219 - 1220
  • [4] Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma
    Yu-Yan Hwang
    Pek-Lan Khong
    Yok-Lam Kwong
    Annals of Hematology, 2017, 96 : 1219 - 1220
  • [5] Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma
    Yasenchak, Christopher A.
    Tseng, Wan-Yu
    Yap, Mark
    Rembert, Debra
    Patt, Debra A.
    LEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3143 - 3149
  • [6] Brentuximab Vedotin Plus AVD for Non-Bulky Limited Stage Classical Hodgkin Lymphoma: A Phase 2 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 17 - 18
  • [7] SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
    Herrera, Alex F.
    Li, Hongli
    Castellino, Sharon M.
    Rutherford, Sarah C.
    Davison, Kelly
    Evans, Andrew G.
    Punnett, Angela
    Constine, Louis S.
    Hodgson, David C.
    Parsons, Susan K.
    Prica, Anca
    Kostakoglu, Lale
    Shipp, Margaret A.
    Laubach, Cara
    Leblanc, Michael L.
    Crump, Michael
    Kahl, Brad S.
    Leonard, John P.
    Kelly, Kara M.
    Smith, Sonali M.
    Friedberg, Jonathan W.
    BLOOD, 2020, 136
  • [8] Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma
    Colunga-Pedraza, Panelperla R. R.
    Ulises Coronado-Alejandro, Edgar
    De La Garza, Fernando
    Gomez Gomez, Eliezer Tomas
    Gomez-De Leon, Andres
    Colunga Pedraza, Julia Esther
    Homero Gutierrez-Aguirre, Cesar
    Cantu Rodriguez, Olga Graciela
    Gomez-Almaguer, David
    BLOOD, 2021, 138
  • [9] Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
    Younes, Anas
    Radford, John
    Ansell, Stephen Maxted
    Gallamini, Andrea
    Kim, Wom Seog
    Feldman, Tatyana A.
    Hamadani, Mehdi
    Chung, Jeanenne
    Wang, Jingyuan
    Huebner, Dirk
    Connors, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
    Hanel, Walter
    Shindiapina, Polina
    Bond, David A.
    Sawalha, Yazeed
    Epperla, Narendranath
    Voorhees, Timothy
    Welkie, Rina Li
    Huang, Ying
    Behbehani, Gregory K.
    Zhang, Xiaoli
    McLaughlin, Eric
    Chan, Wing K.
    Brammer, Jonathan E.
    Jaglowski, Samantha
    Reneau, John C.
    Christian, Beth A.
    William, Basem M.
    Cohen, Jonathon B.
    Baiocchi, Robert A.
    Maddocks, Kami
    Blum, Kristie A.
    Alinari, Lapo
    CANCERS, 2023, 15 (05)
12345